Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKinsey
Dow
AstraZeneca
Harvard Business School

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR FAMVIR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Famvir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00098059 ↗ Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection Completed Novartis Pharmaceuticals Phase 3 2005-02-01 This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients will receive multiple doses of famciclovir alone or with concomitant oral anti-herpes therapy to assess safety and tolerability. Part B will start only after PK data from Part A had been analyzed.
NCT00306787 ↗ Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes Completed Novartis Pharmaceuticals Phase 3 2006-03-01 This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d).
NCT00448227 ↗ Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection Completed Novartis Phase 2 2007-10-01 This study will evaluate the acceptability and safety of famciclovir in infants with herpes simplex infection
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Famvir

Condition Name

Condition Name for Famvir
Intervention Trials
Genital Herpes 2
Healthy 2
Herpes Simplex 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Famvir
Intervention Trials
Herpes Genitalis 2
Herpes Simplex 2
Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Famvir

Trials by Country

Trials by Country for Famvir
Location Trials
United States 56
Canada 7
Panama 2
Australia 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Famvir
Location Trials
Missouri 4
Texas 4
Ohio 3
North Carolina 3
Alabama 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Famvir

Clinical Trial Phase

Clinical Trial Phase for Famvir
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Famvir
Clinical Trial Phase Trials
Completed 6
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Famvir

Sponsor Name

Sponsor Name for Famvir
Sponsor Trials
Novartis Pharmaceuticals 2
Novartis 2
Teva Pharmaceuticals USA 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Famvir
Sponsor Trials
Industry 7
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Baxter
Medtronic
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.